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Atopic dermatitis (AD) is a complex inflammatory skin condition that is not fully under-
stood. Epidermal barrier defects and Th2 immune response dysregulations are thought 
to play crucial roles in the pathogenesis of the disease. A vicious circle takes place 
between these alterations, and it can further be complicated by additional genetic and 
environmental factors. Studies investigating in more depth the etiology of the disease 
are thus needed in order to develop functional treatments. In recent years, there have 
been significant advances regarding in vitro models reproducing important features of 
AD. However, since a lot of models have been developed, finding the appropriate exper-
imental setting can be difficult. Therefore, herein, we review the different types of in vitro 
models mimicking features of AD. The simplest models are two-dimensional culture 
systems composed of immune cells or keratinocytes, whereas three-dimensional skin 
or epidermal equivalents reconstitute more complex stratified tissues exhibiting barrier 
properties. In those models, hallmarks of AD are obtained, either by challenging tissues 
with interleukin cocktails overexpressed in AD epidermis or by silencing expression of 
pivotal genes encoding epidermal barrier proteins. Tissue equivalents cocultured with 
lymphocytes or containing AD patient cells are also described. Furthermore, each 
model is placed in its study context with a brief summary of the main results obtained. 
In conclusion, the described in vitro models are useful tools to better understand AD 
pathogenesis, but also to screen new compounds in the field of AD, which probably will 
open the way to new preventive or therapeutic strategies.
Keywords: atopic dermatitis, in vitro, model, reconstructed epidermis, skin equivalents, epidermal keratinocytes
iNTRODUCTiON
Atopic dermatitis (AD), also referred to as atopic eczema, is one of the most common chronic 
inflammatory skin diseases and the most common form of eczema in childhood. AD is character-
ized by dry erythematous lesions and intense pruritus. At the histological level, acute AD lesions 
mainly involve the epidermis and typically exhibit spongiosis in the suprabasal epidermal layers 
when compared to the normal tissue. Spongiosis is due to alteration in cohesion between keratino-
cytes, resulting in enlarged intercellular spaces suggestive of intercellular edema. Inflammatory 
infiltrate (predominantly lymphocytes) can also be noticed at the epidermal level. Lesional dermis 
is characterized by a marked perivascular T cell infiltrate, predominantly composed of activated 
Abbreviations: AD, atopic dermatitis; IL, interleukin; TSLP(R), thymic stromal lymphopoietin (receptor); LOR, loricrin; IVL, 
involucrin; RHE, reconstructed human epidermis; HSE, human skin equivalent; ECM, extracellular matrix.
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memory/effector T cells. Eosinophils and mast cells (presenting 
variable degranulation stages) can be observed while basophils 
and neutrophils remain scarce. In chronic stages of AD, licheni-
fied lesions appear, typically exhibiting epidermal hyperplasia 
and parakeratotic hyperkeratosis which correspond together to 
thickening of spinous and cornified layers. A high number of 
immunoglobulin E (IgE)-bearing Langerhans cells are present 
inside the epidermis. Slight infiltration by lymphocytes and 
macrophages, together with elevated number of mast cells, 
generally fully granulated, characterize the inflammatory der-
mal infiltrate. More numerous eosinophils can also be observed 
inside the dermis of chronic AD skin lesions (1, 2).
Regarding its pathogenesis, AD is a relapsing disease that is 
complex, multifactorial, and still not completely understood. AD 
can very likely be triggered by both epidermal barrier alterations 
and Th2 immune response dysregulation, each of them being 
potentially responsible for the induction of the other alteration, 
thereby creating a vicious circle responsible for the lesions (3–5). 
Understanding the pathogenesis of AD is further complicated by 
several genetic factors, as well as by diverse environmental fac-
tors like intensive use of soaps and detergents, house dust mites, 
pollutants, allergens, and psychological stress (6–8). Regarding 
genetic predisposition, filaggrin (FLG) gene has been extensively 
studied for variations linked to the context of AD (9–14). Indeed, 
FLG is thought to play a crucial role in the pathophysiology of 
AD because the protein encoded is involved at different levels in 
the formation and maintenance of a correct epidermal barrier 
(15, 16). Indeed, any decrease in FLG expression, as well as in 
its function, may alter aggregation of keratin filaments and thus 
formation of functional corneocytes. Via its metabolites, FLG 
alterations may affect the levels of natural moisturizing factors 
(NMF) and consequently modify skin hydration and possibly its 
pH values. Dehydration of the skin induces xerosis, leading then to 
pruritus and to further alterations of the epidermal barrier, whereas 
any elevation in the skin surface pH enhances activity of proteases 
responsible for the desquamation process and decreases activity 
of enzymes implicated in barrier lipid synthesis (17). All these 
altered processes can weaken the epidermal barrier and enhance 
penetration of allergens/pathogens, inducing further skin inflam-
mation. It is important to note that FLG loss-of-function muta-
tions are not the only reasons responsible for alterations in the role 
of FLG in epidermal barrier formation and maintenance. Indeed, 
AD patients present alteration of their epidermal barrier irrespec-
tively of their FLG genotype (18). Further, a relationship between 
FLG and AD has been proven independent from FLG mutations 
within a French cohort (19) for instance, whereas strong reduc-
tions in FLG expression levels are observed in AD skin (lesional 
and non-lesional) (20, 21). Pellerin and co-workers reported that 
in vitro treatments of keratinocytes with inflammatory cytokines 
highly expressed in AD epidermis, namely IL-4, IL-13, and IL-25, 
were found to reduce FLG expression. Similar findings have been 
reported by further groups (20, 22, 23) and other cytokines like 
IL-17, IL-22, or IL-31 also were found potentially able to decrease 
FLG expression in keratinocytes (24–26). Thus, decrease in FLG 
contribution to the epidermal barrier, either through reduced 
expression or by loss-of-function gene mutations, are strongly 
related to inflammatory conditions. Any downregulation of FLG 
in the epidermis worsens barrier permeability and consequently 
results into triggered inflammation, particularly in lesional areas.
Thus, this limited, but quite well-studied, part of AD patho-
genesis provides very useful information to better understand 
initiation and maintenance of the afore-mentioned vicious circle 
and likely the particularly relapsing nature of the disease.
In addition, AD is considered the initial step of the so-called 
“atopic march,” which corresponds to the consecutive develop-
ment of asthma and/or allergic rhinitis during the life-course 
of 30–50% of AD patients, particularly those who are the most 
severely affected (27–29). The “atopic march” can partly be 
explained through the role played by thymic stromal lymphopoi-
etin (TSLP), a cytokine induced by trauma, microbial infection, 
toll-like receptor activation, or by combinations of inflammatory 
cytokines (30–34). TSLP is found at elevated concentrations in 
AD epidermis (35) and its induction in skin has been reported to 
be accompanied by elevated levels in blood circulation. TSLP is 
believed to be a systemic driver for bronchial hyperresponsiveness 
since blockade of TSLP signaling (36) or inducible gene deletion 
of TSLP in mice keratinocytes (37, 38) prevents occurrence of 
the atopic march, suggesting a potential direct link between AD 
and allergic asthma and/or allergic rhinitis (39–41). Of further 
interest, TSLP released from challenged keratinocytes (31–35) 
would play an important role in the disease by contributing to 
the itch symptoms that characterize the disease (42) but also to 
the Th2-promoting conditions (43–47), thus favoring inflamma-
tion and thereby also barrier alterations (48), playing thereby a 
potentially initiating role in the vicious circle of AD pathogenesis. 
The particular role played by TSLP is described in Figure 1.
Atopic dermatitis is mostly known as an imbalance of the Th2 
immune response as in the acute phase of the disease significant 
increases in gene expression levels of major Th2 cytokines are 
reported. The disease itself is rather characterized by a biphasic 
inflammation and a switch to a Th1 environment is commonly 
reported during chronic phases of AD (1, 55–57). However, situ-
ation is probably more complicated as small increases in Th1 and 
Th17 are also found in acute lesions while a progressive activation 
of Th2 and Th22 cells would also characterize the chronic phase 
of the disease (58).
In regard to the diversity of factors involved in AD pathogene-
sis, it is currently difficult to elaborate treatments that can directly 
target all aspects involved in the etiology of the disease. Existing 
treatments are aimed at restoring epidermal barrier defects and/
or reducing skin inflammation, in combination with avoidance 
of environmental factors that are supposed or demonstrated to 
negatively influence the severity of the disease (59). Studies that 
more deeply investigate mechanisms leading to this pathology 
are, therefore, still required. In order to further investigate the 
development of AD lesions, as well as for preclinical develop-
ment of potentially protecting or resolving treatments and drugs, 
animal models that adequately reproduce symptoms of AD have 
been first generated [for a review see Ref. (60)]. However, mice 
do not spontaneously develop AD and translation of the disease 
condition from experimental mice to humans and vice  versa 
remains questionable because, even though mouse and human 
skin exhibit numerous similarities, crucial differences do also 
exist. For instance, mouse keratinocytes produce fewer epidermal 
FiGURe 1 | Hypothetic simplified representation of the pivotal role played by thymic stromal lymphopoietin (TSLP) in the pathogenesis of acute atopic dermatitis 
(AD) and the interplay between barrier alterations and Th2 immune dysregulation. TSLP released from challenged keratinocytes is able to activate migration of 
Langerhans cells toward draining lymph nodes (35) where they subsequently initiate allergic response by promoting differentiation of naïve CD4+ T cells into 
inflammatory Th2 effectors. TSLP can also directly act on these Th2 effectors to induce their proliferation (43–45). Th2 effector cells produce IL-4, IL-5, IL-13, TNFα, 
while downregulating IFNγ (35), possibly explaining the link observed between barrier alterations and inflammatory conditions. Indeed, among these cytokines, IL-4 
and IL-13 are more particularly known as being able to alter the expression of proteins involved in the epidermal barrier like filaggrin (19, 20, 49), loricrin (LOR) and 
involucrin (IVL) (50), desmoglein 1 and 3 (component of desmosomes) (49, 51), sphingomyelinase and glucocerebrosidase (genes implicated in the synthesis of 
ceramides) (52), or the tight junction component claudin-1 (53). Every cytokine-induced alteration of the epidermal barrier allows conditions more favorable for 
penetration of allergens/pathogens that can then be recognized by dendritic antigen-presenting cells. Processed allergens/pathogens are next presented to naive 
B cells and activate them to eventually produce specific immunoglobulin E (IgE). Such IgE then bind to the high affinity receptor FcεRI expressed on basophils, 
eosinophils, and mast cells. After re-exposure to a previously encountered antigen, the body can respond directly and more strongly. Indeed, when IgE are produced 
in greater amounts, basophils, eosinophils, and mast cells are ready to mediate inflammatory reactions. This immune inflammatory response is known as the allergic 
response. Basophils are able to promote Th2 cytokine response, while mast cells can massively degranulate, notably releasing histamine which induces edema and 
pruritus. IL-4 is known to modulate this allergic response and to induce overproduction of IgE. In addition, TSLP could also play a role in the itch symptoms 
observed in AD patients. Indeed, TSLP activates mast cells to release histamine upon binding to its specific receptor. Even further, keratinocytes directly interact with 
dermal sensory neurons via TSLP, thereby inducing itch (42). Moreover, TSLP may also promote basophil and eosinophil responses. Basophils promote Th2 
cytokine response, while TSLP induces recruitment of eosinophils to Th2 cytokine-associated inflammation sites (54).
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layers (6–7 layers for mouse versus 16–18 layers for human) and 
renewal of the murine tissue happens within 8–10  days only, 
whereas the one in humans lasts for 28  days or so. Obviously, 
mouse skin contains higher numbers and wider diversity of hair 
follicles (less present in tail and ears), and epidermal papillae (also 
known as rete ridges) penetrate less deeply. Mouse skin also lacks 
sweat glands (eccrine sweat glands are exclusively present in the 
pads) and melanocytes in the interfollicular epidermis. Regarding 
potential explanation of mechanisms driving inflammatory skin 
pathologies, it is also important to take into account the differ-
ences in the immune cell population. Indeed, γδ T cells as well as 
dendritic epidermal T cells (DETC) are present in mouse but not 
in human epidermis. These DETC can secrete large amounts of 
pro-inflammatory mediators involved in epidermal communica-
tion with keratinocytes and Langerhans cells (61, 62).
In conclusion, in  vitro models based on human tissues to 
study etiological parameters of inflammatory cutaneous diseases 
like AD have been awaited for a long time, but such models 
are now regularly reported in several various context. In addi-
tion for this requirement of human-based in  vitro models for 
etiological studies, it worth mentioning that, since authorities 
of the European Union have prohibited the testing of cosmetic 
finished products or of their ingredients on laboratory animals 
and they even banned the marketing of cosmetic products tested 
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on animals outside the EU (Regulation (EC) No 1223/2009), 
legal restrictions have further argued for the development and 
assessment of in  vitro models that involve cutaneous tissues. 
Nowadays, in vitro models have to become reliable alternative 
methods for studies about human epidermal pathologies, as well 
as for screening eventual toxic properties on skin of still unevalu-
ated or new chemicals.
Using in vitro model, it is possible to mimic different charac-
teristics of the AD pathology. Indeed, histological features of the 
AD epidermis can be induced, alteration of the epidermal barrier 
can be monitored, some characteristics of inflammation can be 
reproduced and expression of genes can be easily analyzed both 
at the mRNA and protein levels. Several different in vitro models 
regarding AD have been published within the last 10  years in 
the literature. Given the complex interplay between immune 
dysregulations and epidermal barrier alterations in AD, most 
in  vitro models have to focus on these two aspects. However, 
limitations emerge with each model when scientists are looking 
for the best reproduction of the pathology in order to analyze very 
specific aspects or to screen new drugs/cosmetics for potential 
propensities to improve critical aspects of the diseased skin. 
This review first aims at summarizing features of AD that can 
be satisfactorily mimicked in vitro and then provides an update 
about several published in vitro models able to bring some useful 
information about AD pathology. It is, however, important to 
note that this review does not pretend itself to be exhaustive about 
published in  vitro models of AD. It rather focuses on models 
developed to study epidermal characteristics of the disease. For 
each mentioned model, important results reported after the use 
of these models are described but information remains limited to 
key observations.
IN VITRO MODeLS OF AD
Two-Dimensional Culture Systems
Cultures of a single cell type, either immune cells or keratino-
cytes, may be consider as the simplest in vitro models available 
for analysis of cellular phenomena involved etiological processes 
of epidermal inflammatory diseases. Of course, such models do 
not, however, take into account complex structures and interac-
tions within tissues, but present the enormous advantage to allow 
precise evaluation of a specific cell response toward any given 
challenge.
immune Cells
In order to understand parameters regulating roles and abun-
dance of lymphocytes, mast cells, eosinophils, and other immune 
cell types in AD-patients skin, it can be of interest to study each 
cell type, one after the other, to characterize their reaction to 
different stimuli and environmental conditions. Immune cells 
implicated in the pathogenesis of AD can be isolated from 
peripheral blood of AD patients or normal subjects. For instance, 
purified lymphocytes can be studied in vitro, allowing thereby to 
analyze gene expression of surface receptors or investigating cell 
responses toward specialized cytokines or any other potentially 
regulating ligand. For example, it was observed using this type 
of investigation that the frequency of lymphocytes expressing 
the TSLP receptor was correlated with severity of AD disease (63).
Mast cells can also be investigated in vitro after isolation and 
culture in serum-free methylcellulose media containing stem 
cell factor, IL-6, and IL-3. Initially, this type of study has been 
conducted in order to compare proliferation of mast cells isolated 
from donors with normal IgE serum levels, to those isolated 
from AD patients with high serum IgE levels. Both mast cell 
populations exhibited no highlighted difference in proliferation 
and similarly released histamine. Furthermore, significantly 
enhanced histamine release was observed for both types of mast 
cell donors treated with IL-4, suggesting that regulation of mast 
cell function rather happens through environmental stimulation 
by interleukins, than by genetic predisposition in the case of AD 
(64). Conversely, while the number of colonies made of mast cells 
was unchanged, eosinophils and basophils from AD donors did 
exhibit enhanced growth potentials (64).
Basophils or eosinophils, both recognized as actual effectors 
for allergic inflammation, have also been analyzed through 
in  vitro techniques by other investigators. For instance, fibro-
blasts were investigated as monolayers in the presence of culture 
medium containing basophils or eosinophils. Such studies 
interestingly highlighted the requirement for direct intercellular 
contacts during interactions between basophils and fibroblasts, 
while soluble mediators were found able to mediate cross talk 
between eosinophils and fibroblasts. These types of interaction 
in presence of toll-like receptor 2 ligands (e.g., Staphylococcus 
aureus) could thus be considered responsible for secretion of 
pro-inflammatory cytokines, possibly participating thereby in 
inflammatory responses that are typically exacerbated during 
Staphylococcus aureus infections (65).
Keratinocyte Monolayer Cultures
Using culture of cell monolayers, some epidermal differentiation 
of keratinocytes can be achieved by either culture confluence 
(66) or increasing the calcium medium concentration (67), or by 
both. Such cultures are easily performed and remain very useful 
for studying simple basic molecular mechanisms. Incubation 
of either HaCaT cells (49) with IL-4 and IL-13 (10 ng/ml each 
cytokine) or primary human keratinocytes (20) with IL-4 and 
IL-13 (50 ng/ml each), two Th2 cytokines overexpressed in AD 
skin, have been performed to identify their effects on such cells. 
Indeed, during incubation with these cytokines, epidermal cells 
exhibit a notably reduced gene expression for FLG. Further, 
Omori-Miyake and colleagues demonstrated a downregulation 
of expression of keratin 1 and 10, desmoglein 1 and desmocol-
lin-1 via STAT6-dependent mechanisms transduced via IL4RA. 
In addition, this type of analysis allows the demonstration for 
instance that silencing FLG expression using shRNA interference 
can simultaneously induce alterations in the amounts of synthe-
sized cornified envelop-related proteins [expression of keratin 5, 
10, and 14, IVL, and transglutaminase-1 is decreased, while the 
one of loricrin (LOR) is upregulated]. Interestingly, FLG silencing 
does also result in increased release of Th2 cytokines IL-4, IL-5, 
and IL-13, while production of IFNγ is decreased (68).
Mainly used to answer mostly basic questions regarding the 
biology of particular cell types, cultures of monolayers are broadly 
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investigated because they are easy to perform, allow simple 
analytical probing, and are thus efficient at providing results with 
potential significance. Such cultures of human keratinocytes have 
indeed brought methods to test new ideas, as well as data sug-
gestive for explanation of still obscure phenomena. For instance, 
while trying to understand in monolayer cultures of keratinocytes 
how cell signaling produced by cholesterol depletion was affecting 
their phenotypes, transcriptomic homologies were found between 
such keratinocytes and keratinocytes analyzed inside AD lesions 
(69). In other words, a study dealing with plasma membrane lipid 
microdomains opened up questions about their potential rel-
evance and/or relevance of consequences linked to their signaling 
properties in order to understand and investigate AD.
Still, epidermal keratinocytes isolated from AD patients can 
also be cultured and compared to cells of healthy donors. In 
such cultures of keratinocytes, the profile for chemokine produc-
tion inside cells from non-lesional areas of AD patients can be 
compared to normal keratinocytes (70, 71). It was reported this 
way that keratinocytes from AD patients spontaneously express 
elevated levels of granulocyte macrophage colony-stimulating 
factor (71). Keratinocytes from AD patients can further be used 
to evaluate how cytokines affect their phenotype. For example, 
IL-4, IFN-γ, and TNF-α were reported to trigger the production 
of other chemokines, like IL-8, C–C motif chemokine ligand 5, 
RANTES, or C–X–C motif chemokine ligand 10 in keratinocytes 
from non-lesional AD skin (70).
Although keratinocytes cultured as immerged monolayers 
are simple and useful research materials, they nonetheless do not 
stratify and neither produce an efficient barrier. Therefore, the 
development of epidermal in vitro models that produce a func-
tional barrier has become crucial to screen treatments affecting 
this barrier in preclinical studies.
THRee-DiMeNSiONAL SKiN MODeLS
In order to achieve the production of an efficient epidermal bar-
rier, keratinocytes have to be exposed at the air–liquid interface 
while being cultured in conditions that favor their stratification. 
Two models are nowadays commonly available for studies of 
epidermal properties, reconstructed human epidermis (RHE) 
and full-thickness human skin equivalents (HSE), both closely 
mimicking the in vivo characteristics of the human epidermis in 
terms of differentiation, barrier function, and histology (72–77). 
RHE are composed of keratinocytes only, grown at the air–liquid 
interface on inert polycarbonate filters. Conversely, HSE are 
based on dermal-like matrix initially organized before seeding 
growing keratinocytes on top for epidermal stratification and 
keratinization by exposure to air. The dermal-like matrix can 
either be based on de-epidermized dermis or on collagen matri-
ces containing fibroblasts. Three different approaches can be used 
for this last purpose (78):
 (1) The gel approach consists in seeding fibroblasts in extracel-
lular matrix (ECM) components such as collagen, the major 
element of the dermis.
 (2) Dermal substitutes can also be obtained by culturing fibro-
blasts on scaffolds made of synthetic or biological materials 
(79). Collagen mimics many of the structural properties of 
the ECM and can be used as biological scaffold in which 
fibroblasts are then cultured. However, manufacturing a 
collagen scaffold having a precisely controlled 3D pore 
structure, which can be important for cell proliferation and 
migration, is not an easy task. Mechanical properties of scaf-
folds can be improved by using a cryogenic dispenser system 
(80) together with the use of cross-linking chemical agents 
like glutaraldehyde (81) or biological agents like chitosan that 
are then mixed with collagen (79).
 (3) Another possibility is to prepare dermal substitutes thanks to 
the capacity of fibroblasts to secrete their own ECM in vitro. 
After about 28 days of culture, fibroblasts are embedded into 
their own ECM and cell sheets, that can be manipulated, are 
obtained (79).
Both, RHE and HSE models, present advantages and 
disadvantages. Obviously, HSE mimics the epidermis as well 
as the dermal compartment. Further, as diffusion of lipophilic 
substances (e.g., lipid-based creams) is more efficient in vivo than 
in vitro in skin equivalents, adding a dermal-like compartment 
allows partial improvement in vitro (82). However, their produc-
tion takes longer and is more complex. On the other hand, main 
advantages of RHE arise from the fact that they allow evaluation 
of keratinocyte-specific cell type response. In particular, amounts 
of molecules released or secreted by keratinocytes in culture 
medium can be measured using ELISA-like techniques.
Interestingly, in vitro models can be altered in ways that mimic 
AD conditions at the epidermal level, either by incubation with 
cocktails of interleukins overexpressed in the pathology or by 
silencing gene expression of components involved in develop-
ment and structure of the barrier. Finally, keratinocytes, as well 
as other cells types isolated from AD patients, can also be used 
in models.
3-D Challenged Models
Several different cytokines sets have been chosen to create bar-
rier alterations inside cutaneous in vitro models. Depending on 
the cytokines, cell regulations are activated in keratinocytes and 
demonstrate that this kind of treatments can be able to induce 
phenotypic features that recall epidermal lesions seen in AD 
lesions, like widening of intercellular spaces (spongiosis), altera-
tion of expression and localization of differentiation markers, 
and/or modified lipid organization.
For instance, HSE generated on de-epidermized dermis 
were stimulated with IL-4 and IL-13 from day 10 until day 13 of 
reconstruction of the epidermis, using a concentration of 30 ng/
ml for each interleukin (83). IL-4 and IL-13 are two Th2-type 
cytokines that exhibit elevated expression in AD lesional skin 
(20, 23). The treatment induced spongiosis, apoptosis, and 
increased expression of genes that become specifically expressed 
in AD epidermis, like carbonic anhydrase II (CA2) and neuron-
specific Nel-like protein 2 (NELL2) (10, 84). Conversely, the treat-
ment was unable to trigger the expression of psoriasis-associated 
genes, like human beta defensin 2 (hBD2) and elafin. Several other 
studies as well have investigated the epidermal consequences pro-
duced by incubation with these two Th2 interleukins, eventually 
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in combination with other inflammatory molecules. For example, 
IL-25 was added to IL-4 and IL-13 because this cytokine can act 
on both immune cells (85) and keratinocytes, where it can reduce 
expression of FLG (19), explaining thereby the systematic link 
observed between inflammation and barrier disruption in AD 
lesions (22, 86). Consequently, IL-4 and IL-13 (50 ng/ml each) 
were also combined with IL-25 (20 ng/ml) in a study performed 
on RHE model during 48  h (87). Interestingly, the epidermal 
consequences produced by these cytokines were enhanced 
when cholesterol was depleted from the plasma membrane of 
keratinocytes ahead of the interleukin treatment, suggesting that 
plasma membrane lipid microdomains disruption would render 
keratinocytes more sensitive to the Th2 interleukins. In such 
model, spongiosis and hypogranulosis were observed together 
with alterations in the expression of specific AD-markers [FLG, 
LOR, CA2, NELL2, TSLP and hyaluronic acid synthase 3 (HAS3)], 
as well as in barrier functions, as highlighted by transepithelial 
electrical resistance measurements and lucifer yellow permeation 
tests (87). In other studies, Th2 cytokines (IL-4 or IL-13 at 100 ng/
ml each) combined with pro-inflammatory cytokines like TNF-α 
(20 ng/ml) or IL-1α (100 ng/ml) for 48 h have been shown to act 
synergistically in order to induce production of TSLP in human 
skin explants (88). In a RHE model, IL-4, IL-13 (30 ng/ml each), 
and TNF-α (3.5  ng/ml) were further combined to IL-31 
(15 ng/ml), a pruritus-related cytokine, and this cocktail induced 
AD-like features such as decreased expression of epidermal dif-
ferentiation proteins like FLG and LOR, spongiosis, increased 
secretion of TSLP, and alterations of barrier properties that 
concern lipids (89). Indeed, lipid organization was affected as 
the treatment induced a decrease in the level of long chain free 
fatty acids and ester linked ω-hydroxy ceramides. Still in another 
study, IL-22 was combined to TNF-α, IL-4, and IL-13 and applied 
together as an “AD-mix” on RHE at day 10 of epidermis recon-
struction for 48  h at a concentration of 3  ng/ml (90) in order 
to compare this set of interleukins with another “psoriasis-mix” 
set of interleukins containing IL-17, a psoriasis-related cytokine, 
instead of Th2 cytokines IL-4 and IL-13. Using the “AD-mix,” 
one can observe epidermal features of AD including decreased 
expression of FLG, small proline rich proteins (SPRR2A) and 
increased expression of IL-13RA2 (one of the IL-13 receptor 
subunit), together with a weak increase of S100 calcium-binding 
protein A7 expression. Whereas using the “psoriasis-mix,” lighter 
decrease in the expression of FLG is observed, together with a 
stronger increase of S100 calcium-binding protein A7 expression, 
and a weaker increase of SPRR2A and IL-13RA2 are reported.
Still another way to induce in vitro AD-like features in RHE 
was found while combining Poly I:C (10 µg/ml), a toll-like recep-
tor 3 ligand mimicking viral double-stranded RNA, with TNF-α 
(10 ng/ml), IL-4, and IL-13 (50 ng/ml each) at day 14 of epidermis 
reconstruction and for 48 h (91). In this case, spongiosis, altera-
tions of differentiation markers, increase in TSLP expression and 
IL-8 secretion was observed in the RHE, while its transcriptomic 
profile was reminiscent of the one observed in AD keratinocytes.
In vivo, AD epidermis is bathed by a complex mixture of 
cytokines that can produce overlapping, redundant, additive, or 
even opposite effects. Indeed, IL-4, IL-13, IL-22, and IL-25 are all 
able to downregulate expression of differentiation markers such 
as FLG (19, 22, 24, 86). Conversely, TNF-α exhibits only weak 
effects on the expression of keratinocyte differentiation markers. 
Nonetheless, TNF-α appears necessary, in combination with Th2 
cytokines, in order to induce epidermal expression of TSLP. TSLP 
is released in response to a combination of different molecules 
like Th2 cytokines (IL-4 and -13) and pro-inflammatory cytokine 
(TNFα) or poly I:C combined to these cytokines. However, when 
present, IL-17 suppresses this upregulation (92). Regarding other 
opposite effects, both TNF-α and IL-22 induce expression of anti-
microbial peptides such as hBD2, while Th2 cytokines IL-4 and 
IL-13 conversely decrease the levels of beta defensin 2 (93). Still 
more complicated, concentrations and timings of treatment with 
chosen cytokines seems to likely favor different types of tissue 
response. For now, the precise concentrations of these interleu-
kins in skin of AD patients and in healthy skin are unknown yet. 
Thus, one must admit that currently available research data on 
in vitro models have been evaluated in regard of dose-dependent 
effects produced by those cytokines on the expression levels of 
proteins like FLG or TSLP inside the tissue.
Also interesting to mention, because pruritus is an important 
symptom of AD, other factors have been studied in  vitro in 
order to better understand basic mechanisms regulating itch. 
An innervated skin model was set up for this purpose since 
increased innervation is another feature reported about AD skin 
(94, 95). Porcine dorsal root ganglia neurons were seeded in a 
collagen gel in top of which collagen gel comprising fibroblasts 
was added. Keratinocytes were then seeded on top of this scaffold 
in order to reconstruct an epidermis for 12 days at the air–liquid 
interface. That model has allowed to identify that neurons release 
a molecule called calcitonin gene-related peptide able to induce 
epidermal thickening (96). Besides increased innervation, 
elevated numbers of mast cells releasing histamine, among other 
molecules, are also part of AD skin. HSE cultured for 14 days 
were, therefore, incubated with histamine (10 µM) for the whole 
duration of reconstruction or only during the three first days. 
Decreased expression of differentiation markers such as keratin 
1 and 10, FLG, LOR, tight junction proteins, and desmosomal 
proteins was found, likely responsible for alterations in the epi-
dermal barrier function (97).
To summarize, IL-4 and IL-13 seem to be the most crucial, 
probably unavoidable, cytokines which can induce an AD-like 
phenotype in epidermis, in vitro. However, variable interleukin 
cocktails can be added, together with other inflammatory mol-
ecules or neuropeptides, depending on research interests and on 
which target genes treatments or analysis are focused.
3-D Knockdown Models
In both lesional and non-lesional skin of AD patients, FLG 
expression is decreased, due to loss-of-function mutations, or 
irrespective of any particular FLG genotype (19, 21). Organotypic 
skin models containing knockdown of FLG in keratinocytes 
have been set up. Two studies have analyzed FLG knockdown 
in HSE by means of siRNAs (98, 99). Kuchler et al. (87) showed 
that FLG silencing performed in keratinocytes used to produce 
HSE grown at the air–liquid interface for 14 days, disturbed the 
development of the stratum corneum and also induced spongi-
osis. An increased susceptibility to irritating exposure, as well as 
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altered transepidermal absorption of testosterone, but not of 
caffeine, was also reported. Using siRNA as well but in HSE ana-
lyzed after 7 days of epidermis reconstitution, Mildner et al. (99) 
have described increased permeability of the epidermal barrier 
to the lucifer yellow dye, hypogranulosis, enhanced activation 
of caspase-3 after UVB irradiation, but no alteration of lipid 
composition or of keratinocyte differentiation in the knockdown 
tissue. While using an shRNA procedure to also suppress FLG 
expression in a RHE model grown for 11 days, Pendaries and col-
laborators (100) reported hypogranulosis and increased barrier 
permeability of the lucifer yellow dye, together with a reduced 
number of keratinocyte layers, reduced cornified layer thickness, 
and decreased levels of the NMF, potentially responsible for 
the increased UV sensitivity already reported by Kuchler and 
colleagues (98). However, unlike Mildner and co-workers (99), 
alterations were reported in the mRNA and protein expression 
of components deeply involved in the epidermal differentiation 
process (100). Indeed, filaggrin-2 (FLG2), LOR, caspase 14 
and bleomycin hydrolase were altogether reported as reduced 
conversely to the increased expression of corneodesmosin (100). 
Knockdown of FLG using shRNA was also performed in HSE 
generated using N/TERT keratinocytes (101). In this model, no 
alteration is reported neither regarding epidermal morphology 
(keratin 10, LOR, and proliferation marker ki67 were analyzed), 
neither lipid composition nor epidermal permeability (butyl-
PABA permeation studies were performed). The discrepancies 
reported by the different groups could probably be attributed 
to the fact that different targets/issues are analyzed, therefore, 
further analyses would be interesting regarding this domain. 
A summary of the different studies regarding FLG knockdown in 
3D models is available in Niehues et al. (102).
Interestingly, FLG silencing by mean of siRNAs in skin 
equivalents, cultivated for 14 days at the air–liquid interface, has 
been shown to render HSE more sensitive to the Th2 cytokines 
IL-4 and IL-13 (15 ng/ml of each when combined), increasing 
their effects on the model (93). These consequences include his-
tological changes such as epidermal thickening and alterations in 
values of the superficial cutaneous pH measured. Furthermore, 
several effects induced by the deficiency in FLG expression, 
such as the upregulated expression of IVL or of occludin, were 
hampered by the addition of IL-4 and IL-13 (93).
Filaggrin-2 knockdown in RHE cultured for 11 days was also 
created by the use of shRNA production (103). Silencing FLG2 in 
keratinocytes of RHE led them to produce a thinner epidermis 
exhibiting parakeratosis, a compact cornified layer, and several 
alterations in the keratinocyte differentiation program includ-
ing reduced processing of FLG, hornerin, corneodesmosin and 
reduced levels of caspase 14 and bleomycin hydrolase. A less 
acidic pH and an increased sensitivity to UVB was also attributed 
to FLG2 knockdown in RHE (103).
An alternative to the preparation of knockdown epidermal 
3-D models has been developed by the use of keratinocytes 
that carry mutation(s) in genes of interest. Such methods avoid 
knockdown-derived off-target effects, but depend on availability 
of patient biopsies. For example, FLG-null keratinocytes can be 
obtained from ichthyosis vulgaris patients and be used to create 
pathological HSE that can be compared to healthy HSE (102). In 
this case, no alteration in the expression of keratin 10, IVL and 
transglutaminase-1 differentiation markers was reported, whereas 
some decrease in occludin and claudin-4 expression could be 
observed at protein level, affecting tight junctions. Despite such a 
decrease, no alteration in the epidermal barrier function could be 
reported using lucifer yellow and biotin permeation assays. Such 
FLG-null HSE were further analyzed after incubation with IL-4 
and IL-13 (50 ng/ml for each cytokine), a treatment which again 
produces alterations in the expression of several differentiation 
markers (102).
Finally, explants from healthy and non-lesional human AD 
skin, harboring or not FLG mutations, have been cultured on 
dermal equivalents (104). Expression profile for most proteins 
remains identical in culture to their counterpart established 
in vivo, regardless of the presence of FLG mutations. This kind 
of model has allowed assessing that FLG mutations neither alter 
expression of the kallikrein 5 protease involved in cutaneous 
desquamation or the expression of the lympho-epithelial Kazal 
type related protease inhibitor (LEKTI).
Skin equivalents Using AD Cells
In order to understand potential cross talk between fibroblasts 
and keratinocytes in the context of AD, organotypic skin cultures 
consisting of fibroblasts derived from perilesional atopic skin and 
healthy keratinocytes, as well as healthy fibroblasts and atopic 
keratinocytes have generated for comparison with controls (105). 
That study demonstrated that atopic fibroblasts contribute to the 
particular pathological microenvironment of keratinocytes by 
releasing paracrine mediators which are responsible for hyper-
proliferation and reduced expression of differentiation markers 
in keratinocytes. Moreover, healthy fibroblasts have been shown 
able to rescue alterations in stratification and differentiation of 
keratinocytes as they are usually observed in AD epidermis. 
Interestingly, cocultures made of the two atopic cell types could 
not form any stratified epidermis in the model, the effects being 
partially dependent on expression of leukemia inhibitory factor 
by fibroblasts.
Skin equivalents Containing Lymphocytes
Many cytokines are being produced by lymphocytes. Thus, in 
order to better mimic the in  vivo situation, as well as in order 
to create a model that is adequate to test drugs or other actives 
which could target together the epidermal and immune compart-
ments, cocultures of keratinocytes and lymphocytes have been 
developed. Two different organotypic skin equivalents have been 
developed using HaCaT cells cocultured with lymphocytes (106). 
For both procedures, HSE were prepared using dermal matrix 
containing fibroblasts. In the first case, the epidermal tissue was 
removed from its dermal matrix and then cocultured in the 
presence of activated T cells. In the other procedure described 
by Engelhart and his colleagues (94), the whole HSE was trans-
ferred onto a collagen matrix containing the lymphocytes, coated 
with cell-free collagen mixture that acts as an adhesive for the 
HSE. Using this integrated organotypic skin model, spongi-
osis, keratinocyte apoptosis, reduced expression of E-cadherin, 
expression of intercellular adhesion molecule-1, upregulation of 
neurotrophin-4, as well as elevated levels of pro-inflammatory 
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cytokines and chemokines were reported (94). In addition, this 
integrated epidermal model was used to show positive effects 
of anti-inflammatory drugs on the epidermal barrier through 
measurements of transepithelial electrical resistance.
Cross talk between T  cells and keratinocytes has also been 
studied in a skin equivalent generated on de-epidermized dermis 
(107). In such model, CD4+ T cells were introduced between the 
transwell membrane and the dermal side of a fully developed 
skin equivalent. Th1 and Th17 polarization of the CD4+ T cells 
could be obtained and was able to induce psoriasis-like epidermal 
inflammation. However, induction of Th2 polarization of the 
CD4+ T cells was not successful, indicating that this model still 
requires refinements to adequately mimic features of AD.
CONCLUSiON AND PeRSPeCTiveS
Several and quite various options for in vitro human models have 
been chosen to allow studies of AD pathogenesis (Figure  2). 
Every option uses different rationales aimed at creating altera-
tions in otherwise normal tissues. They were also chosen for their 
potentiality in evaluating preventive and/or therapeutic treat-
ments. To date, published studies highlight the requirement for 
therapeutic strategies which can target restoration of a functional 
epidermal barrier or which can inhibit T cells from overproduc-
ing cytokines. They also suggest that therapeutic approaches 
which could more specifically block the action of a particular 
cytokine, or of its receptor, are based on highly relevant data.
Interestingly, in aforementioned coculture models (106, 107), 
authors have shown that drugs acting on inflammation, like 
dexamethasone, tacrolimus, or cyclosporine A, are able to sup-
press inflammatory cell infiltrates by inhibiting the cytokine 
production triggered by T cells present in the model. Such drugs 
were also tested on HSE previously treated with IL-4 and IL-13; 
however, in this case, no improvement in epidermal spongiosis 
and no reduction in the expression of CA2 and NELL2 could 
be observed, very likely because of the absence of immune cells 
in the model (83). Thus, other treatments more specifically 
targeting epidermal features should now be tested to appreciate 
the interest of immune-free models.
It is, however, important to keep in mind that these in vitro 
models represent a simplification of the in vivo situation as they 
remain models only and that it will probably never be possible to 
reproduce all human features of the pathology in such models. 
Furthermore, it is also worth to mention that different features 
observed in AD skin, at the histological level as well as at the 
molecular level, could refer to general inflammation or epider-
mal hyperplasia. It is, therefore, required to combine a panel of 
various readouts but in general, finding the “best” readouts in a 
biological or pathological model is never an easy task. Therefore, 
regarding AD, in order to help scientists to set up correct and 
efficient readouts, several studies have used keratinocytes derived 
from AD patients and compared them with cells from healthy, or 
even psoriatic, keratinocytes in order to identify specific tran-
scriptomic or proteomic patterns (108–113). Another important 
issue to take into account about readouts is the type of model 
that is used. Indeed, cross talks between the different cell types 
of the model, like keratinocytes and fibroblasts, may influence 
significantly the results. For example, fibroblasts in the dermal 
matrix can improve keratinocyte differentiation while sustain-
ing epidermal viability (114). In addition, fibroblasts can also 
produce TSLP (35). Thus, when fibroblasts are included in the 
dermal matrix of HSE, a special attention must be paid to take 
this factor into account when assessing hypothesis and drawing 
conclusions. Furthermore, environmental stress conditions are 
known to play a role in the development of AD [for extensive 
review see Ref. (8)]. Intensive use of soap (4), proteases from 
house dust mites, exposure to pollutants and chemicals (4, 115), 
and psychological stress (116, 117) notably have been reported as 
risk factors able to play some role in the development of AD. It 
could be envisaged to add topically soap, detergents or house dust 
mites to in vitro models in order to mimic some environmental 
factors that could play a role in the development of AD. However, 
factors like psychological stress are less obvious to integrate into 
an in vitro model, also because underlying mechanisms are still 
incompletely understood.
Despite in vitro studies are performed on simplified models, 
they might nevertheless bring better understanding of a pathol-
ogy, while trying to answer rather basic questions. As an example, 
a typical morphological feature of AD inside the epidermis is the 
appearance of intercellular spongiosis. Spongiosis is a well-known 
characteristic of this disease but is not yet fully understood. It is 
characterized by loss of cohesion between keratinocytes together 
with some influx apparently associated with an accumulation 
of hyaluronan (HA) (118, 119). HA is indeed reported as being 
increased in intercellular spaces of lesional AD epidermis in vivo, 
in simultaneity with an increased expression of the HA synthase 
HAS3 (119, 120). Interestingly, enhancement of HA synthesis 
and deposition in RHE is also simultaneous with treatment of 
the epidermis with Th2 cytokines, especially with IL-4 treatment 
performed after cholesterol depletion from keratinocyte plasma 
membrane (87, 121). Whether any relationship exists between 
epidermal regulations of HA concentration (120, 122) and spon-
giosis observed during AD would be interesting to investigate. 
Is the elevated HA concentration a cause, or a consequence of 
spongiosis? This question could be answered using in vitro mod-
els where HA could be withdrawn by mean of incubation with 
a hyaluronidase that degrades HA into small fragments, or by 
inhibiting epidermal HA synthesis, either pharmacologically or 
by means of siRNA or shRNA targeting the expression of HAS 
enzymes.
It would be important to further investigate implication 
of Th17 and Th22 cells in the context of AD as the classical 
paradigm of AD as a “Th2” disease has recently been challenged. 
Indeed, Th17 is mostly associated with psoriasis as it is more 
induced in psoriasis than in AD (123). However, Th17 cells have 
been demonstrated in AD and associated with severity of the 
disease (124, 125). IL-17 expression was found at higher levels 
in acute AD skin lesions than in chronic lesions or healthy skin, 
even if in a lesser extent compared with psoriasis lesions (123). 
Interestingly, IL-17 could also negatively regulate expression of 
FLG as well as of tight junction proteins ZO-1 and ZO-2, des-
mosomes, e-cadherin, and various integrins (25). IL-17 is a key 
inducer of expression of antimicrobial genes (123), potentially 
explaining why psoriasis patients are less frequently subjected 
FiGURe 2 | Summary of published models developed for in vitro studies of atopic dermatitis (AD) features. Different types of in vitro models can be used in regards 
to the research focus, from the most simple ones consisting of only one cellular type (named here 2D models) to more complex models reconstituting the different 
layers of the epidermis (called here 3D models). 2D models are used in order to characterize behavior of one given cellular type whereas 3D models are more 
commonly used with the aim of trying to reproduce some features of the pathology. Within these two types of models, immortalized cells can be used, but in order 
to be closer to the in vivo situation, primary cells are often used. Cells derived directly from patients are probably the most relevant but also the more complicated to 
obtain and the most limited. While performing 3D models, two different types of models are commonly used: human skin equivalents (HSE) or reconstructed human 
epidermis (RHE). HSE reproduce the epidermis on top of a dermis equivalent, whereas RHE only reproduce the different layers of the epidermis. HSE are more 
complicated to produce but display the advantage to present a dermal compartment whereas RHE allow evaluation of keratinocyte-specific type of responses and 
analysis of released or secreted molecules in the culture medium. HSE or RHE can both be challenged by interleukin cocktails and genetically modified. And 
cocultures with immune cells could be performed in both cases.
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to skin infections than AD patients. Regarding Th22 cells, these 
are also reported as increased in AD skin and correlated with 
disease severity (126). IL-22 would, in RHE, affect expression of 
FLG, induce epidermal hyperplasia, and upregulate expression 
of pro-inflammatory molecules belonging to the S100 family of 
calcium-binding proteins (127). Further interesting, IL-17 and 
IL-22 could act synergistically to regulate notably gene expression 
of AMPs (128) and S. aureus, that frequently affects AD patients, 
could induce production of Th17  cells (129). In summary, the 
understanding of the pathogenic mechanisms is still in progress 
and further research concerning this area is needed. Further, 
more data regarding comprehension of the transit from the acute 
to the chronic stage of the disease and vice versa would also be 
useful.
To conclude, several skin models can mimic in vitro the path-
ological situation of AD, especially at particular points of view. 
However, no model is currently able to entirely resume in vitro 
the overall characteristics of AD. Therefore, investigations on 
this disease have to take into account the balance between advan-
tages and disadvantages of the multiple available models before 
choosing the most appropriate one(s) and before collecting data 
in relation with specifically targeted scientific issues.
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